Jiaojiao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Jiaojiao Xu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer L. Pluznick
Department of Physiology, Johns Hopkins School of Medicine, Baltimore, USA
6 shared publications Helen R. Warren
Centre of Clinical Pharmacology & Precision Medicine, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
2 shared publicationsKunal Gupta
Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 shared publications- Markus M. Rinschen
III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 shared publications - Rira Choi
Department of Biomedical Engineering, Yale University, New Haven, CT, USA
2 shared publications - Aaron W. Miller
Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, USA
1 shared publication
Latest Publications
- 29 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (1) , 36-48
Microbes and GFR in Health and CKD in Mice
Key Points: Microbes regulate GFR in health and CKD in mice. Tubuloglomerular feedback initially contributes to the microbial modulation of GFR. Background: Microbes are implicated in a variety of host physiologic and pathophysiologic processes. In this study, we tested the hypothesis that microbes modulate GFR in health and CKD. Methods: To uncover the effect of gut microbiota on kidney function in health and in a CKD model, we examined GFR, plasma creatinine, and kidney histology in mice when gut microbes were manipulated. Results: In healthy mice, GFR was significantly increased when gut microbiota were either suppressed (oral antibiotics) or absent (germ-free). In mice challenged with adenine diet to induce CKD with impaired GFR, suppressing gut microbes with oral antibiotics also increased GFR. In females on an adenine diet, oral antibiotics increased GFR versus adenine alone on weeks 4 and 6. In males, oral antibiotics elevated GFR on week 2. Adenine diet significantly increased plasma creatinine and kidney fibrosis; this was suppressed by oral antibiotics in both sexes. To explore the mechanism, we tested the hypothesis that altered tubuloglomerular feedback contributes to elevated GFR using the sodium-glucose cotransporter 2 inhibitor empagliflozin; empagliflozin impairs Na + reabsorption in the proximal tubule, altering tubuloglomerular feedback. Empagliflozin impaired antibiotics-induced GFR increases on week 3 but not week 5, suggesting that altered tubuloglomerular feedback contributes to the initial increase in GFR. Conclusions: The microbiome plays a key role in “setting” baseline GFR by a mechanism that partially involves tubuloglomerular feedback, and suppressing gut microbes can elevate GFR even in CKD mice.
- 29 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (1) , 36-48
Microbes and GFR in Health and CKD in Mice
Key Points: Microbes regulate GFR in health and CKD in mice. Tubuloglomerular feedback initially contributes to the microbial modulation of GFR. Background: Microbes are implicated in a variety of host physiologic and pathophysiologic processes. In this study, we tested the hypothesis that microbes modulate GFR in health and CKD. Methods: To uncover the effect of gut microbiota on kidney function in health and in a CKD model, we examined GFR, plasma creatinine, and kidney histology in mice when gut microbes were manipulated. Results: In healthy mice, GFR was significantly increased when gut microbiota were either suppressed (oral antibiotics) or absent (germ-free). In mice challenged with adenine diet to induce CKD with impaired GFR, suppressing gut microbes with oral antibiotics also increased GFR. In females on an adenine diet, oral antibiotics increased GFR versus adenine alone on weeks 4 and 6. In males, oral antibiotics elevated GFR on week 2. Adenine diet significantly increased plasma creatinine and kidney fibrosis; this was suppressed by oral antibiotics in both sexes. To explore the mechanism, we tested the hypothesis that altered tubuloglomerular feedback contributes to elevated GFR using the sodium-glucose cotransporter 2 inhibitor empagliflozin; empagliflozin impairs Na + reabsorption in the proximal tubule, altering tubuloglomerular feedback. Empagliflozin impaired antibiotics-induced GFR increases on week 3 but not week 5, suggesting that altered tubuloglomerular feedback contributes to the initial increase in GFR. Conclusions: The microbiome plays a key role in “setting” baseline GFR by a mechanism that partially involves tubuloglomerular feedback, and suppressing gut microbes can elevate GFR even in CKD mice.
- Top Cited PapersOpen Access
- 28 July 2025
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 21 (10) , 1-15
Microbiota and kidney disease: the road ahead
More than 850 million individuals worldwide, accounting for 10–15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota — a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.
- 28 July 2025
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 21 (10) , 1-15
Top Cited PapersOpen AccessMicrobiota and kidney disease: the road ahead
More than 850 million individuals worldwide, accounting for 10–15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota — a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.
- Open Access
- 22 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (12) , eadk1487
An evolutionarily conserved olfactory receptor is required for sex differences in blood pressure
Sex differences in blood pressure are well-established, with premenopausal women having lower blood pressure than men by ~10 millimeters of mercury; however, the underlying mechanisms are not fully understood. We report here that sex differences in blood pressure are absent in olfactory receptor 558 knockout (KO) mice. Olfr558 localizes to renin-positive cells in the kidney and to vascular smooth muscle cells. Female KOs exhibit increased blood pressure and increased pulse wave velocity. In contrast, male KO mice have decreased renin expression and activity, altered vascular reactivity, and decreased diastolic pressure. A rare OR51E1 (human ortholog) missense variant has a statistically significant sex interaction effect with diastolic blood pressure, increasing diastolic blood pressure in women but decreasing it in men. In summary, our findings demonstrate an evolutionarily conserved role for OLFR558/OR51E1 to mediate sex differences in blood pressure.
- 22 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (12) , eadk1487
Open AccessAn evolutionarily conserved olfactory receptor is required for sex differences in blood pressure
Sex differences in blood pressure are well-established, with premenopausal women having lower blood pressure than men by ~10 millimeters of mercury; however, the underlying mechanisms are not fully understood. We report here that sex differences in blood pressure are absent in olfactory receptor 558 knockout (KO) mice. Olfr558 localizes to renin-positive cells in the kidney and to vascular smooth muscle cells. Female KOs exhibit increased blood pressure and increased pulse wave velocity. In contrast, male KO mice have decreased renin expression and activity, altered vascular reactivity, and decreased diastolic pressure. A rare OR51E1 (human ortholog) missense variant has a statistically significant sex interaction effect with diastolic blood pressure, increasing diastolic blood pressure in women but decreasing it in men. In summary, our findings demonstrate an evolutionarily conserved role for OLFR558/OR51E1 to mediate sex differences in blood pressure.
- 16 August 2023
- Published by Elsevier in Medicina Clinica
- Vol. 162 (1) , 1-8
Anti-parietal cell antibodies as a potential biomarker for interstitial lung disease associated with primary Sjögren's syndrome
- 16 August 2023
- Published by Elsevier in Medicina Clinica
- Vol. 162 (1) , 1-8
Anti-parietal cell antibodies as a potential biomarker for interstitial lung disease associated with primary Sjögren's syndrome
- Open Access
An evolutionarily conserved olfactory receptor is required for sex differences in blood pressure
Sex differences in blood pressure are well-established, with premenopausal women having lower blood pressure than men by ∼10mmHg; however, the underlying mechanisms are not fully understood. We report here that olfactory receptor 558 (Olfr558), which has not previously been studied in non-olfactory tissues, localizes to vascular smooth muscle cells in numerous tissues including the kidney and heart. In the kidney, Olfr558 colocalizes with renin (a hormone that plays a key role in blood pressure regulation) in the renal afferent arteriole. Based on the localization of Olfr558, we hypothesized that Olfr558 plays a role in blood pressure regulation. We find that sex differences in blood pressure are intact in Olfr558 wildtype (WT) mice, but, are absent in Olfr558 knockout (KO) mice. We find that male KO mice have lowered diastolic blood pressure, decreased renin expression and activity, and altered vascular reactivity. Female KO mice exhibit increased blood pressure and increased pulse wave velocity, indicating increased vascular stiffness. The human ortholog of Olfr558, OR51E1, was previously identified as a locus associated with diastolic blood pressure. We report here that a rare OR51E1 missense variant has a statistically significant sex interaction effect with diastolic blood pressure, increasing diastolic blood pressure in women but decreasing it in men. In addition, we characterize how two different clinically relevant OR51E1 variants influence OR51E1 signaling in vitro . In sum, our findings demonstrate an evolutionarily conserved role for Olfr558/OR51E1 to mediate sex differences in blood pressure by altering renin, vascular reactivity, and arterial stiffness.
Open AccessAn evolutionarily conserved olfactory receptor is required for sex differences in blood pressure
Sex differences in blood pressure are well-established, with premenopausal women having lower blood pressure than men by ∼10mmHg; however, the underlying mechanisms are not fully understood. We report here that olfactory receptor 558 (Olfr558), which has not previously been studied in non-olfactory tissues, localizes to vascular smooth muscle cells in numerous tissues including the kidney and heart. In the kidney, Olfr558 colocalizes with renin (a hormone that plays a key role in blood pressure regulation) in the renal afferent arteriole. Based on the localization of Olfr558, we hypothesized that Olfr558 plays a role in blood pressure regulation. We find that sex differences in blood pressure are intact in Olfr558 wildtype (WT) mice, but, are absent in Olfr558 knockout (KO) mice. We find that male KO mice have lowered diastolic blood pressure, decreased renin expression and activity, and altered vascular reactivity. Female KO mice exhibit increased blood pressure and increased pulse wave velocity, indicating increased vascular stiffness. The human ortholog of Olfr558, OR51E1, was previously identified as a locus associated with diastolic blood pressure. We report here that a rare OR51E1 missense variant has a statistically significant sex interaction effect with diastolic blood pressure, increasing diastolic blood pressure in women but decreasing it in men. In addition, we characterize how two different clinically relevant OR51E1 variants influence OR51E1 signaling in vitro . In sum, our findings demonstrate an evolutionarily conserved role for Olfr558/OR51E1 to mediate sex differences in blood pressure by altering renin, vascular reactivity, and arterial stiffness.
- 1 October 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2127-2137
Short-Chain Fatty Acid Receptors and Blood Pressure Regulation: Council on Hypertension Mid-Career Award for Research Excellence 2021
The gut microbiome influences host physiology and pathophysiology through several pathways, one of which is microbial production of chemical metabolites which interact with host signaling pathways. Short-chain fatty acids (SCFAs) are a class of gut microbial metabolites known to activate multiple signaling pathways in the host. Growing evidence indicates that the gut microbiome is linked to blood pressure, that SCFAs modulate blood pressure regulation, and that delivery of exogenous SCFAs lowers blood pressure. Given that hypertension is a key risk factor for cardiovascular disease, the examination of novel contributors to blood pressure regulation has the potential to lead to novel approaches or treatments. Thus, this review will discuss SCFAs with a focus on their host G protein-coupled receptors including GPR41 (G protein-coupled receptor 41), GPR43, and GPR109A, as well as OLFR78 (olfactory receptor 78) and OLFR558. This includes a discussion of the ligand profiles, G protein coupling, and tissue distribution of each receptor. We will also review phenotypes relevant to blood pressure regulation which have been reported to date for Gpr41, Gpr43, Gpr109a , and Olfr78 knockout mice. In addition, we will consider how SCFA signaling influences physiology at baseline, and, how SCFA signaling may contribute to blood pressure regulation in settings of hypertension. In sum, this review will integrate current knowledge regarding how SCFAs and their receptors regulate blood pressure.
- 1 October 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2127-2137
Short-Chain Fatty Acid Receptors and Blood Pressure Regulation: Council on Hypertension Mid-Career Award for Research Excellence 2021
The gut microbiome influences host physiology and pathophysiology through several pathways, one of which is microbial production of chemical metabolites which interact with host signaling pathways. Short-chain fatty acids (SCFAs) are a class of gut microbial metabolites known to activate multiple signaling pathways in the host. Growing evidence indicates that the gut microbiome is linked to blood pressure, that SCFAs modulate blood pressure regulation, and that delivery of exogenous SCFAs lowers blood pressure. Given that hypertension is a key risk factor for cardiovascular disease, the examination of novel contributors to blood pressure regulation has the potential to lead to novel approaches or treatments. Thus, this review will discuss SCFAs with a focus on their host G protein-coupled receptors including GPR41 (G protein-coupled receptor 41), GPR43, and GPR109A, as well as OLFR78 (olfactory receptor 78) and OLFR558. This includes a discussion of the ligand profiles, G protein coupling, and tissue distribution of each receptor. We will also review phenotypes relevant to blood pressure regulation which have been reported to date for Gpr41, Gpr43, Gpr109a , and Olfr78 knockout mice. In addition, we will consider how SCFA signaling influences physiology at baseline, and, how SCFA signaling may contribute to blood pressure regulation in settings of hypertension. In sum, this review will integrate current knowledge regarding how SCFAs and their receptors regulate blood pressure.
- 1 June 2022
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 322 (6) , C1279-C1288
Key amino acids alter activity and trafficking of a well-conserved olfactory receptor
In this study, we elucidate factors that regulate the trafficking and activity of a well-conserved olfactory receptor (OR), olfactory receptor 558 (Olfr558), and its human ortholog olfactory receptor 51E1 (OR51E1). Results indicate that butyrate activates Olfr558/OR51E1 leading to the production of cAMP, and evokes Ca2+ influx. We also find olfactory G protein (Golf) increases cAMP production induced by Olfr558/OR51E1 activation but does not affect trafficking. Given the 93% sequence identity between OR51E1 and Olfr558, it is surprising to note that OR51E1 has significantly more surface expression yet similar total protein expression. We find that replacing the Olfr558 N-terminus with that of OR51E1 significantly increases trafficking; in contrast, there is no change in surface expression conferred by the OR51E1 TM2, TM3, or TM4 domains. A previous analysis of human OR51E1 single nucleotide polymorphisms (SNPs) identified an A156T mutant primarily found in South Asia as the most abundant (albeit still rare). We find that the OR51E1 A156T mutant has reduced surface expression and cAMP production without a change in total protein expression. In sum, this study of a well-conserved olfactory receptor identifies both protein regions and specific amino acid residues that play key roles in protein trafficking and also elucidates common effects of Golf on the regulation of both the human and murine OR.
- 1 June 2022
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 322 (6) , C1279-C1288
Key amino acids alter activity and trafficking of a well-conserved olfactory receptor
In this study, we elucidate factors that regulate the trafficking and activity of a well-conserved olfactory receptor (OR), olfactory receptor 558 (Olfr558), and its human ortholog olfactory receptor 51E1 (OR51E1). Results indicate that butyrate activates Olfr558/OR51E1 leading to the production of cAMP, and evokes Ca2+ influx. We also find olfactory G protein (Golf) increases cAMP production induced by Olfr558/OR51E1 activation but does not affect trafficking. Given the 93% sequence identity between OR51E1 and Olfr558, it is surprising to note that OR51E1 has significantly more surface expression yet similar total protein expression. We find that replacing the Olfr558 N-terminus with that of OR51E1 significantly increases trafficking; in contrast, there is no change in surface expression conferred by the OR51E1 TM2, TM3, or TM4 domains. A previous analysis of human OR51E1 single nucleotide polymorphisms (SNPs) identified an A156T mutant primarily found in South Asia as the most abundant (albeit still rare). We find that the OR51E1 A156T mutant has reduced surface expression and cAMP production without a change in total protein expression. In sum, this study of a well-conserved olfactory receptor identifies both protein regions and specific amino acid residues that play key roles in protein trafficking and also elucidates common effects of Golf on the regulation of both the human and murine OR.
- Open Access
- 4 December 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Prediction for HBsAg seroconversion in children with chronic hepatitis B
Background: To establish a prediction of HBsAg seroconversion in children with chronic hepatitis B (CHB), so as to help clinicians to choose therapeutic strategy. Methods: A total of 63 children with HBeAg-positive CHB aged 1 to 17 years, who admitted to the fifth medical center of Chinese PLA general hospital and treated with interferon α (IFNα) 48 weeks were enrolled, the clinical data were measured. Based on the results of HBsAg seroconversion (HBsAg < 0.05 IU/mL and anti-HBsAg > 10 IU/L) at week 48, the patients were divided into HBsAg seroconversion (S) group and non-HBsAg seroconversion (NS) group. Multivariate COX regression was used to identify the impact factors associated with HBsAg seroconversion. A novel prediction index was established and the area under the receiver operating characteristic curve (AUROC) was used to assess the prediction for HBsAg seroconversion. Results: The 63 patients were divided into S group (20.6%, 13/63) and NS group (79.4%, 50/63). Univariate and multivariate analysis identified age, baseline intrahepatic cccDNA and serum HBsAg levels were independent impact factors for HBsAg seroconversion. Intrahepatic cccDNA was positively correlated with serum HBsAg (r = 0.464, p = 0.000). AUROC of HBV cccDNA was 0.83 (95% CI 0.71 to 0.95) and AUROC of baseline HBsAg was 0.77 (95% CI 0.61 to 0.92). Intrahepatic cccDNA ≤ 0.08 log10 copies/106 cell is regarded as cutoff value, the positive predictive value(PPV) and negative predictive value(NPV) for HBsAg seroconversion were 86.8% and 60.0%, respectively, with a sensitivity of 92.0% and specificity of 56.2%. HBsAg ≤ 3.68 log10 IU/mL is used as cut off value, the PPV and NPV for HBsAg seroconversion were 91.2% and 56.3%, respectively; the sensitivity and specificity was 86.0% of 69.2%, respectively. There was no statistical difference between them for predicting HBsAg seroconversion (p = 0.146). Conclusions: HBsAg seroconversion can be predicted by the baseline serum HBsAg or intrahepatic cccDNA in children with CHB. Using the index, clinicians can choose more reasonable therapeutic strategy and reduce the waste of medical resources.
- 4 December 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Open AccessPrediction for HBsAg seroconversion in children with chronic hepatitis B
Background: To establish a prediction of HBsAg seroconversion in children with chronic hepatitis B (CHB), so as to help clinicians to choose therapeutic strategy. Methods: A total of 63 children with HBeAg-positive CHB aged 1 to 17 years, who admitted to the fifth medical center of Chinese PLA general hospital and treated with interferon α (IFNα) 48 weeks were enrolled, the clinical data were measured. Based on the results of HBsAg seroconversion (HBsAg < 0.05 IU/mL and anti-HBsAg > 10 IU/L) at week 48, the patients were divided into HBsAg seroconversion (S) group and non-HBsAg seroconversion (NS) group. Multivariate COX regression was used to identify the impact factors associated with HBsAg seroconversion. A novel prediction index was established and the area under the receiver operating characteristic curve (AUROC) was used to assess the prediction for HBsAg seroconversion. Results: The 63 patients were divided into S group (20.6%, 13/63) and NS group (79.4%, 50/63). Univariate and multivariate analysis identified age, baseline intrahepatic cccDNA and serum HBsAg levels were independent impact factors for HBsAg seroconversion. Intrahepatic cccDNA was positively correlated with serum HBsAg (r = 0.464, p = 0.000). AUROC of HBV cccDNA was 0.83 (95% CI 0.71 to 0.95) and AUROC of baseline HBsAg was 0.77 (95% CI 0.61 to 0.92). Intrahepatic cccDNA ≤ 0.08 log10 copies/106 cell is regarded as cutoff value, the positive predictive value(PPV) and negative predictive value(NPV) for HBsAg seroconversion were 86.8% and 60.0%, respectively, with a sensitivity of 92.0% and specificity of 56.2%. HBsAg ≤ 3.68 log10 IU/mL is used as cut off value, the PPV and NPV for HBsAg seroconversion were 91.2% and 56.3%, respectively; the sensitivity and specificity was 86.0% of 69.2%, respectively. There was no statistical difference between them for predicting HBsAg seroconversion (p = 0.146). Conclusions: HBsAg seroconversion can be predicted by the baseline serum HBsAg or intrahepatic cccDNA in children with CHB. Using the index, clinicians can choose more reasonable therapeutic strategy and reduce the waste of medical resources.
- 21 April 2016
- Published by Walter de Gruyter GmbH in Zeitschrift für Naturforschung C
- Vol. 71 (5-6) , 111-114
Jaspiferin G, a new isomalabaricane-type triterpenoid from the sponge Jaspis stellifera
A new isomalabaricane-type triterpenoid, jaspiferin G (1), together with four known isomalabaricane-type triterpenoids, isogeoditin A (2), 13-(E)-isogeoditin A (3), jaspolide E (4), and 22,23-dihydrostellettin D (5), was isolated from the marine sponge Jaspis stellifera. The structures were elucidated on the basis of spectroscopic data (1H and 13C NMR, 1H-1H COSY, HSQC, HMBC, and ROESY) and mass spectrometry.
- 21 April 2016
- Published by Walter de Gruyter GmbH in Zeitschrift für Naturforschung C
- Vol. 71 (5-6) , 111-114
Jaspiferin G, a new isomalabaricane-type triterpenoid from the sponge Jaspis stellifera
A new isomalabaricane-type triterpenoid, jaspiferin G (1), together with four known isomalabaricane-type triterpenoids, isogeoditin A (2), 13-(E)-isogeoditin A (3), jaspolide E (4), and 22,23-dihydrostellettin D (5), was isolated from the marine sponge Jaspis stellifera. The structures were elucidated on the basis of spectroscopic data (1H and 13C NMR, 1H-1H COSY, HSQC, HMBC, and ROESY) and mass spectrometry.